Clinical Trial

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-22.
Trial Details
NCT Number NCT07662811
Lead Sponsor Shanghai Chest Hospital
Conditions Non-Small Cell Lung Cancer
Enrollment 396 participants
Start Date 2026-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-29